Events
At the World Vaccine Congress, antimicrobial resistance as a global health crisis grabbed top billing.
At the World Vaccine Congress this week, Novavax presented data suggesting that its protein nanoparticle booster generated immune responses that could protect against severe infection.
With data from the Phase III trial of donanemab expected in Q2, Eli Lilly presented the first clinical results from its next anti-amyloid antibody, remternetug, at AD/PD 2023.
The past two decades were all about nucleic acid reading and writing. The next is about delivering DNA and RNA, Yogev Debbi, CEO of Mana.bio, told BioSpace in an interview.
Moderna may seek the FDA’s accelerated approval for its personalized cancer vaccine, president Stephen Hoge said Monday.
With the results from the CLEAR outcomes study, Esperion is poised for a major inflection in sales and is targeting blockbuster status, said CEO Sheldon Koenig on an investor call Monday.
Here are some tips to help you nail virtual interviews and networking events so you can be prepared for BioSpace’s Virtual Talent Connect on March 9.
Artificial intelligence and machine learning could change the face of cancer diagnostics. BioSpace spoke with the University of Waterloo, Gina Life and OncoHost to find out how.
Takeda’s vedolizumab met its primary endpoint in the Phase III GRAPHITE study, significantly improving event-free survival in patients with acute graft-versus-host disease.
As biopharma executives sought funding last week at the BIO CEO & Investor Conference, the strategic mindset could be summed up in three words: flexibility, creativity and concession.
PRESS RELEASES